- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06089616
Une étude pour documenter et décrire plus en détail l'innocuité et l'efficacité à long terme du palovarotène chez les participants atteints de fibrodysplasie ossifiante progressive (FOP) (FOPal)
Une étude de registre observationnel international pour décrire plus en détail l'innocuité et l'efficacité à long terme du palovarotène chez les patients atteints de fibrodysplasie ossifiante progressive (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ipsen Clinical Study Enquiries
- Numéro de téléphone: see email
- E-mail: clinical.trials@ipsen.com
Lieux d'étude
-
-
-
Edmonton, Canada
- Recrutement
- Edmonton Clinic Health Academy (ECHA)- University of Alberta
-
Oakville, Canada
- Actif, ne recrute pas
- Bone Research and Education Centre
-
Toronto, Canada
- Recrutement
- University Health Network (UHN) - Toronto General
-
-
-
-
California
-
San Francisco, California, États-Unis, 94103
- Recrutement
- The Regents of the University of California
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
La description
Inclusion Criteria :
- Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
- Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
- Currently participating in a palovarotene clinical trial;
- Currently participating in any interventional clinical trial for FOP;
- Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: OTHER
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Exposed Cohort
Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) |
|
Unexposed Cohort
Participants untreated with palovarotene |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
Délai: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC). |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
Délai: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
Délai: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
Délai: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Nombre de poussées
Délai: De 12 mois avant l'inclusion Référence jusqu'à onze ans.
|
De 12 mois avant l'inclusion Référence jusqu'à onze ans.
|
|
|
Nombre d'emplacements impactés par participant
Délai: De la ligne de base et annuelle jusqu'à onze ans.
|
De la ligne de base et annuelle jusqu'à onze ans.
|
|
|
Evolution du lieu impacté (combien de fois un lieu est impacté) par lieu
Délai: Depuis la ligne de base et annuellement jusqu'à onze ans.
|
Depuis la ligne de base et annuellement jusqu'à onze ans.
|
|
|
Dose moyenne / année de palovarotène pour les participants atteints de FOP exposés et non exposés au palovarotène pour un traitement chronique
Délai: De la ligne de base et tous les six mois à onze ans.
|
De la ligne de base et tous les six mois à onze ans.
|
|
|
Dose moyenne / cycle du palovarotène pour les participants atteints de FOP exposés et non exposés au palovarotène pour un traitement de poussée
Délai: De la ligne de base et tous les six mois à onze ans.
|
De la ligne de base et tous les six mois à onze ans.
|
|
|
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
Délai: From Baseline and every six months up to eleven years.
|
The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in use of assistive devices
Délai: From Baseline and every six months up to eleven years.
|
Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
Délai: From Baseline and every six months up to eleven years.
|
Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
Délai: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
Délai: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
Délai: From Baseline and every six months up to eleven years.
|
The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Délai: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
Délai: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:
|
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
Délai: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
Délai: From Baseline and every six months up to eleven years.
|
The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit. |
From Baseline and every six months up to eleven years.
|
|
Number of flare-up outcomes
Délai: From Baseline and every six months up to eleven years.
|
Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported. |
From Baseline and every six months up to eleven years.
|
|
Flare-up Duration
Délai: From Baseline and every six months up to eleven years.
|
Flare-up duration will be assessed by body location and overall, at each visit. |
From Baseline and every six months up to eleven years.
|
|
Movement mobility change
Délai: From Baseline and annually up to eleven years.
|
Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement) |
From Baseline and annually up to eleven years.
|
|
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
Délai: From Baseline and every six months up to eleven years.
|
The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected. |
From Baseline and every six months up to eleven years.
|
|
Percentage of participants with any fractures overall
Délai: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Change from Baseline in annualized number of fractures by body location and overall
Délai: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Incidence of pregnancy
Délai: From Baseline and every month up to 30 days after the last palovarotene dose.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified |
From Baseline and every month up to 30 days after the last palovarotene dose.
|
|
Description of pregnancy characteristics and outcomes
Délai: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of pregnancy related Adverse Events (AEs)
Délai: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Délai: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
Délai: From Baseline and every six months up to eleven years.
|
Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in height z-score
Délai: From Baseline and every six months up to eleven years.
|
Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Mean difference between chronological age and bone age
Délai: From Baseline and every six months up to eleven years.
|
Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Frequency of premature physeal closure (PPC) overall
Délai: From baseline up to 30 days after the last palovarotene dose
|
Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From baseline up to 30 days after the last palovarotene dose
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Ipsen Medical, Director, Ipsen
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CLIN-60120-453
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Délai de partage IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Critères d'accès au partage IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .